A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis (RePhlect)

Bristol-Myers Squibb (BMS)

Status: Enrolling

Conditions: Psoriasis

Treatments: Drug: Apremilast; Drug: Deucravacitinib

Study type: Observational

Funder types: Industry

Identifiers

NCT05744466

IM011-1105

Details and patient eligibility

About

The purpose of this study is to understand the comparative effectiveness of deucravacitinib versus apremilast in adults with plaque psoriasis.

Enrollment: 1,500 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Have been diagnosed with plaque psoriasis by a dermatologist
• Newly initiating an eligible medication for enrollment (i.e., deucravacitinib, apremilast)
• Actively enrolled in the CorEvitas Psoriasis Registry and have documented consent to allow copies of information from the registry be used for research purposes

Exclusion criteria

• Participation (current or planned) in an interventional clinical trial (does not include observational registry or study)
• Restart of treatments with the study eligible therapies previously received at any time during the participants' treatment history

Trial design

1,500 participants in 2 patient groups

Cohort 1

Description:

Participants that have initiated deucravacitinib

Treatment:

Drug: Deucravacitinib

Cohort 2

Description:

Participants that have initiated apremilast

Treatment:

Drug: Apremilast